The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kasimova L.N.

Privolzhsky Research Medical University

Svyatogor M.V.

Privolzhsky Research Medical University

Angedonia in the structure of affective disorders: therapeutic opportunities

Authors:

Kasimova L.N., Svyatogor M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(11): 116‑122

DOI: 10.17116/jnevro2019119111116

Read: 36247 times

Download PDF (RU)
Contact the author
Table of contents

ANGEDONIA IN THE STRUCTURE OF AFFECTIVE DISORDERS: THERAPEUTIC OPPORTUNITIES
ANGEDONIA IN THE STRUCTURE OF AFFECTIVE DISORDERS: THERAPEUTIC OPPORTUNITIES

To cite this article:

Kasimova LN, Svyatogor MV. Angedonia in the structure of affective disorders: therapeutic opportunities. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(11):116‑122. (In Russ.)
https://doi.org/10.17116/jnevro2019119111116

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The gut microbiota in bipo­lar diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Online phenotypes of depression symptoms are asso­ciated with poly­genic risk scores of soma­tic diseases in a popu­lation-based cohort. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):122-131
Subjective sleep quality evaluation in patients with neuromyelitis optica spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):57-61
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
A personalized approach to the treatment of chro­nic tension headache and como­rbid mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):51-57
Anti­depressants as addi­tional drugs for human brain gliomas. Burdenko's Journal of Neurosurgery. 2024;(6):97-102
Asso­ciation between the vita­min D level and depression in the elde­rly people in the Euro­pean North of Russia. Russian Journal of Preventive Medi­cine. 2024;(12):107-113
Atopic dermatitis and skin toxic reactions: comparative characteristics, psychosomatic aspe­cts and patient mana­gement tactics. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):744-752
Abstract:

Anhedonia is one of the core features of depression. The article considers the place of anhedonia in the structure of affective disorders, its influence on the prognosis and effectiveness of therapy. The authors stress that various manifestations of anhedonia must be considered in correlation with the basic ability to feel pleasure. Therapy of anhedonia is not always effective. According to literature, agomelatin occupies a leading position among the drugs that reduce anhedonia.

Keywords:

anhedonia
affective disorders
depression
effectiveness of therapy
agomelatin
valdoxan

Authors:

Kasimova L.N.

Privolzhsky Research Medical University

Svyatogor M.V.

Privolzhsky Research Medical University

Received:

09.10.2019

Accepted:

15.10.2019

Close metadata

References:

  1. World Health Organization, 2017. Depression and Other Common Mental Disorders: Global Health Estimates [Internet]. World Health Organization, Geneva, Switzerland.
  2. Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. JAMA Psychiatry. 2015;72(6):603-611.  https://doi.org/10.1001/jamapsychiatry.2015.0071
  3. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014. Sci Rep. 2018;8(1):2861. Published 2018 Feb 12.  https://doi.org/10.1038/s41598-018-21243-x
  4. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization; 1993.
  5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
  6. World Health Organization. World health statistics 2016: monitoring health for the SDGs sustainable development goals. World Health Organization, 2016.
  7. Zimmerman M, Balling C, Chelminski I, Dalrymple K. Understanding the severity of depression: Which symptoms of depression are the best indicators of depression severity? Compr Psychiatry. 2018;87:84-88.  https://doi.org/10.1016/j.comppsych.2018.09.006
  8. Gao K, Sweet J, Su M, Calabrese JR. Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample. Asian J Psychiatr. 2017;27:40-47.  https://doi.org/10.1016/j.ajp.2017.02.013
  9. Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019;92:109-117.  https://doi.org/10.1016/j.pnpbp.2019.01.002
  10. Ducasse D, Loas G, Dassa D, Gramaglia C, Zeppegno P, Guillaume S, Courtet P. Anhedonia is associated with suicidal ideation independently of depression: A meta‐analysis. Depression and Anxiety. 2018;35(5):382-392.  https://doi.org/10.1002/da.22709
  11. Ho N, Sommers M. Anhedonia: a concept analysis. Arch Psychiatr Nurs. 2013;27(3):121-129.  https://doi.org/10.1016/j.apnu.2013.02.001
  12. Liu WH, Wang LZ, Shang HR, Shen Y, Li Z, Cheung EF, Chan RC. The influence of anhedonia on feedback negativity in major depressive disorder. Neuropsychologia. 2014;53:213-220.  https://doi.org/10.1016/j.neuropsychologia.2013.11.023
  13. Clark DC, Fawcett J, Salazar-Grueso E, Fawcett E. Seven-month clinical outcome of anhedonic and normally hedonic depressed inpatients. Am J Psychiatry. 1984;141(10):1216-1220. https://doi.org/10.1176/ajp.141.10.1216
  14. Schrader GD. Does anhedonia correlate with depression severity in chronic depression? Compr Psychiatry. 1997;38(5):260-263.  https://doi.org/10.1016/S0010-440X(97)90057-2
  15. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, Mors O, Elkin A, Williamson RJ, Schmael C, Henigsberg N, Perez J, Mendlewicz J, Janzing JGE, Zobel A, Skibinska M, Kozel D, Stamp AS, Bajs M, Placentino A, Barreto M, McGuffin P, Aitchison KJ. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychological Medicine. 2008;38(2):289-300.  https://doi.org/10.1017/S0033291707001730
  16. Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, McGuffin P. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: A secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) Study. The Journal of Clinical Psychiatry. 2011;72(11):1478-1484. https://doi.org/10.4088/JCP.10m06419
  17. Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, Hauser J, Dernovsek MZ, Souery D, Bajs M, Maier W, Aitchison KJ, Farmer A, McGuffin P. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Medicine. 2012;42(5):967-980.  https://doi.org/10.1017/S0033291711001905
  18. McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, Wagner KD, Asarnow JR, Ryan ND, Birmaher B, Shamseddeen W, Mayes T, Kennard B, Spirito A, Keller M, Lynch FL, Dickerson JF, Brent DA. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012;51(4):404-411.  https://doi.org/10.1016/j.jaac.2012.01.011
  19. Vinckier F, Gourion D, Mouchabac S. Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur Psychiatry. 2017;44:1-8.  https://doi.org/10.1016/j.eurpsy.2017.02.485
  20. Rizvi SJ, Quilty LC, Sproule BA, Cyriac A, Bagby RM, Kennedy SH. Development and validation of the dimensional anhedonia rat-ing scale (DARS) in a community sample and individuals with major depression. Psychiatry Res. 2015;229(1-2):109-119.  https://doi.org/10.1016/j.psychres.2015.07.062
  21. Thomsen KR. Measuring anhedonia: impaired ability to pursue, experience, and learn about reward. Front Psychol. 2015;6:1409. https://doi.org/10.3389/fpsyg.2015.01409
  22. Winer ES, Jordan DG, Collins AC. Conceptualizing anhedonias and implications for depression treatments. Psychol Res Behav Manag. 2019;12:325-335.  https://doi.org/10.2147/PRBM.S159260
  23. Stepanov IL. Anhedonia as a diagnostic, prognostic and maladaptive factor in various types of depression (phenomenology, dynamics, principles of therapy): Dis. ... d-ra med. nauk. M. 2004. (In Russ.).
  24. Krylov VI. Anhedonia in disorders of the affective and schizophrenic spectrum: psychopathological features, diagnostic and prognostic value. Psikhiatriya i Psikhofarmakoterapiya im. P.B. Gannushkina. 2014;1:28-33. (In Russ.).
  25. Shankman SA, Katz AC, DeLizza AA, Sarapas C, Gorka SM, Campbell ML. The different facets of anhedonia and their associations with different Psychopathologies. In: Ritsner MS, editor. Anhedonia: A Comprehensive Handbook Vol I. New York, NY: Springer; 2014. https://doi.org/10.1007/978-94-017-8591-4
  26. Netter P, Hennig J. Discriminating depression, physical and social anhedonia by neurotransmitter related challenge tests. Psychology. 2016;7(03):275-285.  https://doi.org/10.4236/psych.2016.73030
  27. Olino TM, Horton LE, Versella MV. A comparison of psychometric and convergent validity for social anhedonia and social closeness. Psychol Assess. 2016;28(11):1465-1474. https://doi.org/10.1037/pas0000291
  28. Klein D. Endogenomorphic depression. A conceptual and terminological revision. Arch Gen Psychiatry. 1974;31:447-454.  https://doi.org/10.1001/archpsyc.1974.01760160005001
  29. Fletcher K, Parker G, Paterson A, Fava M, Iosifescu D, Pizzagalli DA. Anhedonia in melancholic and non-melancholic depressive disorders. J Affect Disord. 2015;184:81-88.  https://doi.org/10.1016/j.jad.2015.05.028
  30. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537-555.  https://doi.org/10.1016/j.neubiorev.2010.06.006
  31. Szczypiński JJ, Mateusz G. Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia? Reviews in the Neurosciences. 2017;29(7):727-744.  https://doi.org/10.1515/revneuro-2017-0091
  32. Treadway MT, Bossaller NA, Shelton RC, Zald DH. Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol. 2012;121(3):553-558.  https://doi.org/10.1037/a0028813
  33. Treadway MT. The Neurobiology of Motivational Deficits in Depression — An Update on Candidate Pathomechanisms. In: Simpson E, Balsam P. (eds) Behavioral Neuroscience of Motivation. Current Topics in Behavioral Neurosciences, vol 27. Springer. 2015;27:337-355.  https://doi.org/10.1007/7854_2015_400
  34. Yang XH, Huang J, Zhu CY, Wang YF, Cheung EF, Chan RC, Xie GR. Motivational deficits in effort-based decision making in individuals with subsyndromal depression, first-episode and remitted depression patients. Psychiatry Research. 2014;874-882.  https://doi.org/10.1016/j.psychres.2014.08.056
  35. Gard DE, Gard MG, Kring AM, John OP. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J Res Pers. 2006;40(6):1086-1102. https://doi.org/10.1016/j.jrp.2005.11.001
  36. Baskin-Sommers AR, Foti D. Abnormal reward functioning across substance use disorders and major depressive disorder: Considering reward as a transdiagnostic mechanism. International Journal of Psychophysiology. 2015;98(2):227-239.  https://doi.org/10.1016/j.ijpsycho.2015.01.011
  37. Chen C, Takahashi T, Nakagawa S, Inoue T, Kusumi I. Reinforcement learning in depression: A review of computational research. Neurosci Biobehav Rev. 2015;55:247-267.  https://doi.org/10.1016/j.neubiorev.2015.05.005
  38. Whitton AE, Treadway MT, Pizzagalli DA. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry. 2015;28:7-12.  https://doi.org/10.1097/YCO.0000000000000122
  39. Bress JN, Hajcak G. Self-report and behavioral measures of reward sensitivity predict the feedback negativity. Psychophysiology. 2013;50:610-616.  https://doi.org/10.1111/psyp.12053
  40. Di Nicola M, De Risio L, Battaglia C, Camardese G, Tedeschi D, Mazza M, Martinotti G, Pozzi G, Niolu C, Di Giannantonio M, Siracusano A, Janiri L. Reduced hedonic capacity in euthymic bipolar subjects: A trait-like feature? Journal of Affective Disorders. 2013;147:446-450.  https://doi.org/10.1016/j.jad.2012.10.004
  41. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41.  https://doi.org/10.1001/2013.jamapsychiatry.4
  42. Verdolini N, Dean J, Elisei S, Quartesan R, Zaman R, Agius M. Bipolar disorder: the importance of clinical assessment in identifying prognostic factors—an audit. Part 2: mixed state features and rapid cycling. Psychiatr Danub. 2014;26(1):301-308. 
  43. van Zessen R, Phillips JL, Budygin EA, Stuber GD. Activation of VTA GABA neurons disrupts reward consumption. Neuron. 2012;73(6):1184-1194. https://doi.org/10.1016/j.neuron.2012.02.016
  44. Winer ES, Veilleux JC, Ginger EJ. Development and validation of the specific loss of interest and pleasure scale (SLIPS). J Affect Disord. 2014;152-154, 193-201.  https://doi.org/10.1016/j.jad.2013.09.010
  45. Winer ES, Nadorff MR, Ellis TE, Allen JG, Herrera S, Salem T. Anhedonia predicts suicidal ideation in a large psychiatric inpatient sample. Psychiatry Res. 2014;218(1-2):124-128.  https://doi.org/10.1016/j.psychres.2014.04.016
  46. Loas G. Anhedonia and risk of suicide: an overview Anhedonia: A Comprehensive Handbook Volume II. New York, NY: Springer; 2014. https://doi.org/10.1007/978-94-017-8591-4
  47. Zielinski MJ, Veilleux JC, Winer ES, Nadorff MR. A short-term longitudinal examination of the relations between depression, anhedonia, and self-injurious thoughts and behaviors in adults with a history of self-injury. Compr Psychiatry. 2017;73:187-195.  https://doi.org/10.1016/j.comppsych.2016.11.013
  48. Corruble E, de Bodinat C, Belaidi C, Goodwin GM. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16:2219-2234. https://doi.org/10.1017/S1461145713000679
  49. Loas G, Lefebvre G, Rotsaert M, Englert Y. Relationships between anhedonia, suicidal ideation and suicide attempts in a large sample of physicians. PLoS One. 2018;13(3):e0193619. https://doi.org/10.1371/journal.pone.0193619
  50. Blum K, Oscar-Berman M, Gardner EL, Simpatico T, Braverman ER, Gold MS. Neurogenetics and neurobiology of dopamine in anhedonia. In: Ritsner M.S., editor. Anhedonia: A Comprehensive Handbook. Vol. I. New York, NY: Springer; 2014. https://doi.org/10.1007/978-94-017-8591-4
  51. Rolls ET, Grabenhorst F. The orbitofrontal cortex and beyond: from affect to decision-making. Prog Neurobiol. 2008;86(3):216-244.  https://doi.org/10.1016/j.pneurobio.2008.09.001
  52. Linnet J. Neurobiological underpinnings of reward anticipation and outcome evaluation in gambling disorder. Front Behav Neurosci. 2014;8:100.  https://doi.org/10.3389/fnbeh.2014.00100
  53. Treadway MT, Zald DH. Translational models of dopaminergic mechanisms for motivational deficits in anhedonic patients. In: Ritsner M.S., editor. Anhedonia: A Comprehensive Handbook vol I. New York, NY: Springer; 2014. https://doi.org/10.1007/978-94-017-8591-4
  54. Padrao G, Mallorqui A, Cucurell D, Marco-Pallares J, Rodriguez-Fornells A. Neurophysiological differences in reward processing in anhedonics. Cogn Affect Behav Neurosci. 2013;13:102-115.  https://doi.org/10.3758/s13415-012-0119-5
  55. Thomsen KR, Whybrow PC, Kringelbach ML. Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain. Front Behav Neurosci. 2015;9:1-23.  https://doi.org/10.3389/fnbeh.2015.00049
  56. Salamone JD, Correa M, Yohn S, Lopez Cruz L, San Miguel N, Alatorre L. The pharmacology of effort-related choice behavior: dopamine, depression, and individual differences. Behav Process. 2016;127:3-17.  https://doi.org/10.1016/j.beproc.2016.02.008
  57. Deutschenbaur L, Beck J, Kiyhankhadiv A, Mühlhauser M, Borgwardt S, Walter M, Hasler G, Sollberger D, Lang UE. Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:325-333.  https://doi.org/10.1016/j.pnpbp.2015.02.015
  58. Rizvi SJ, Pizzagalli DA, Sproule BA, Kennedy SH. Assessing anhedonia in depression: potentials and pitfalls. Neurosci Biobehav Rev. 2016;65:21-35.  https://doi.org/10.1016/j.neubiorev.2016.03.004
  59. Barbano MF, Cador M. Opioids for hedonic experience and dopamine to get ready for it. Psychopharmacology. 2007;191(3):497-506.  https://doi.org/10.1007/s00213-006-0521-1
  60. Carlezon WA, Krystal AD. Kappa-opioid antagonists for psychiat-ric disorders: from bench to clinical trials. Depress Anxiety. 2016;33(10):895-906.  https://doi.org/10.1002/da.22500
  61. De Berardis D, Fornaro M, Orsolini L, Iasevoli F, Tomasetti C, de Bartolomeis A, Serroni N, De Lauretis I, Girinelli G, Mazza M, Valchera A, Carano A, Vellante F, Matarazzo I, Perna G, Martinotti G, Di Giannantonio M. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in «real-world», everyday clinical practice. CNS Spectrums. 2017;22(4):342-347.  https://doi.org/10.1017/S1092852916000572
  62. Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, Onofrj M, Janiri L, Di Giannantonio M. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012;32(4):487-491.  https://doi.org/10.1097/JCP.0b013e31825d6c25
  63. Burstein O, Franko M, Gale E, Handelsman A, Barak S, Motsan S, Shamir A, Toledano R, Simhon O, Hirshler Y, Chen G, Doron R. Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. PLoS ONE. 2017;12(11):e0188043. https://doi.org/10.1371/journal.pone.0188043
  64. Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life sciences. 2018;210:177-184.  https://doi.org/10.1016/j.lfs.2018.09.003
  65. McIntyre RS, Gommoll C, Chen C, Ruth A. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. CNS Spectrums. 2016;21(5):385-392.  https://doi.org/10.1017/S1092852915000899
  66. Jouvent R, Le Houezec J, Payan C, Mikkelsen H, Fermanian J, Millet V, Dufour H. Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation. Psychiatry Res. 1998;79(3):267-275. 
  67. Lally N, Nugent AC, Luckenbaugh DA, Niciu M.J, Roiser JP, Zarate CA. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. Journal of Psychopharmacology. 2015;29(5):596-607.  https://doi.org/10.1177/0269881114568041
  68. Rizvi SJ, Geraci J, Ravindran A, Kennedy SH. Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue. J Clin Psychopharmacol. 2014;34(6):755-759.  https://doi.org/10.1097/JCP.0000000000000211
  69. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627.  https://doi.org/10.1016/S2215-0366(16)30065-7
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.